CAMBRIDGE, Mass., Feb. 28, 2018 /PRNewswire/ — Brammer Bio ("Brammer"), a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapy companies, supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases. For more information, please visitwww.rarediseaseday.org. Brammer is a sponsor and will participate in the MassBio Forum event inBoston, MA.
Mark Bamforth, CEO of Brammer, commented, "Brammer is actively engaged in supporting the development of gene therapy products for our clients and their patients. These gene therapy products include an increasing number targeting rare diseases, as some of these treatments are demonstrating outstanding safety and efficacy. The Brammer team consists of 350 extraordinary employees focused exclusively on serving the gene therapy needs of our clients and their patients." Brammer offers end-to-end CDMO services from Phase 1 through commercial clinical manufacturing from our sites inFloridaandMassachusetts.
TheCambridgefacility in the heart of Kendall Square houses state-of-the-art equipment, with cleanroom suites specially designed to accommodate the commercial manufacturing of a broad-range of viral vector manufacturing process technologies for leading edge cell and gene therapy products. The company's 49,000 square-foot distribution center inSomerville, Massachusetts, provides high-quality storage and clinical and commercial distribution capabilities.
TheFloridaoperations and facilities are focused on supporting early phase gene therapy clinical manufacturing capacity.
About Ampersand Capital Partners Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Visitwww.ampersandcapital.com.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
